We serve Chemical Name:Mercury(II) Sulfide CAS:1344-48-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Mercury(II) Sulfide
CAS.NO:1344-48-5
Synonyms:Mercury(II) sulfide red;MERCURY(II) SULFIDE;Mercuric sulfide red;EINECS 215-696-3;MFCD00011046
Molecular Formula:HgS
Molecular Weight:232.65500
HS Code:
Physical and Chemical Properties:
Melting point:584ºC
Boiling point:584ºC
Density:8.1 g/mL at 25ºC
Index of Refraction:
PSA:32.09000
Exact Mass:233.94300
LogP:0.64570
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2025
Packing Group:II
Contact us for information like Mercury(II) sulfide red chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00011046 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 215-696-3 Use and application,MERCURY(II) SULFIDE technical grade,usp/ep/jp grade.
Related News: As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Mercury(II) Sulfide manufacturer We manufacture APIs and drug manufacturers make medicines from APIs. Mercury(II) Sulfide supplier The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. Mercury(II) Sulfide vendor The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. Mercury(II) Sulfide factory Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion.
